LEXICON PHARMACEUTICALS, INC. Proceeds from Sale of Real Estate
LEXICON PHARMACEUTICALS, INC. (LXRX) reported Proceeds from Sale of Real Estate of $2.40 million for the 1-month period ending 2011-06-30, per its 10-K filed 2014-03-07.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfRealEstate · last filed 2014-03-07
- 2011-06-30: Proceeds from Sale of Real Estate 1 month $2.40M.
| Period end | Proceeds from Sale of Real Estate 1 month |
|---|---|
| 2011-06-30 | $2.40M 10-K · filed 2014-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |